The Brigham and Women’s Hospital Cardiac Amyloidosis Program, led by Rodney H. Falk, MD, is the only clinical program in the U.S. focusing exclusively on cardiac amyloidosis. This unique program was established in order to help fill a significant void in the diagnosis and treatment of systemic amyloidosis, with a view to acquiring a better understanding of cardiac amyloidosis and improving care for patients who have the disease.
Amyloidosis refers to a group of diseases, caused by deposits of abnormal proteins known as amyloid, affecting one or more organ systems in the body. Deposition of amyloid in the heart is known as cardiac amyloidosis, and whether it occurs solely in the heart or in conjunction with other organs, it is the presence of amyloidosis in the heart that determines the severity and outcome of the disease and its treatments. Impaired heart function caused by amyloid deposition often results in excess build-up of fluid in the body. This condition, known as congestive heart failure, is associated with congestion in the lungs and liver.
Learn more about the Cardiac Amyloidosis Program at Brigham and Women’s Hospital.
Read the Advancing Treatment of Cardiac Amyloidosis video transcript.